CelcuityCELC +6.95%26 PB Ratio is 87.03 as of Jun. 24, 2026. GuruFocus rates CELC with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,233 Biotechnology companies, Celcuity ranks worse than 98.78% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), Celcuity's share price is $96.34. Celcuity's Book Value per Share for the quarter that ended in Mar. 2026 was $1.11. Hence, Celcuity's PB Ratio of today is 87.03.
The historical rank and industry rank for Celcuity's PB Ratio or its related term are showing as below:
CELC'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 87.27
Current: 86.83
During the past 11 years, Celcuity's highest PB Ratio was 87.27. The lowest was 0.00. And the median was 0.00.
CELC's PB Ratio is ranked worse than 98.78% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs CELC: 86.83
During the past 12 months, Celcuity's average Book Value Per Share Growth Rate was -33.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -30.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 17.60% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Celcuity was 69.00% per year. The lowest was -30.40% per year. And the median was 34.65% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Celcuity PB Ratio Related Terms
Celcuity PB Ratio Historical Data
* Premium members only.
The historical data trend for Celcuity's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celcuity's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celcuity PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celcuity's PB Ratio distribution charts can be found below:
* The bar in red indicates where Celcuity's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Celcuity's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Celcuity (CELC) has a PB Ratio of 87.03 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Celcuity and its competitors. According to the industry distribution chart, Celcuity ranks #1218 out of 1233 companies in the Biotechnology industry, placing it in the top 98.8%.
Is Celcuity's PB Ratio too high?
Celcuity's current PB Ratio is 87.03. The Biotechnology industry median PB Ratio is 2.83. Celcuity's value of 87.03 is 2975.3% above this industry median. Based on the distribution chart, Celcuity ranks #1218 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celcuity has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's PB Ratio compare to PTGX and SYRE?
According to the Biotechnology industry distribution chart, Celcuity ranks #1218 out of 1233 companies for PB Ratio. This places Celcuity in the lower half of its industry. The industry median PB Ratio is 2.83. Celcuity's value of 87.03 is 2975.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celcuity's current PB Ratio of 87.03 is 2975.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Celcuity and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celcuity's current PB Ratio is 87.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (CELC) has a current PB Ratio of 87.03. The current PB Ratio is 87.03 and 2975.3% above the Biotechnology industry median of 2.83. Celcuity's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Celcuity (CELC), the current PB Ratio is 87.03 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
26GF Score
Get the complete analysis for CELC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CELC has been successfully added to your 
